Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib

Komaki, Reo; Miyagaki, Tomomitsu; Nakajima, Kiyokazu; Mitsuishi, Shuhei; Kishi, Arisa; Miyano, Kaoru; Okano, Tatsuro; Takeuchi, Sora; Suzuki, Shotaro; Kadono, Takafumi

doi:10.1111/1346-8138.15872

Cited by 9 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, psoriasiform reaction during dupilumab treatment has been reported (Fowler et al, 2019, Napolitano et al, 2019, Schrom et al, 2020 with increased expression of IL-23A in the lesional skin (Napolitano et al, 2021). Arthritis and enthesitis during the dupilumab treatment have also reported (Bridgewood et al, 2020, de Wijs et al, 2020c, Ishibashi et al, 2020, Komaki et al, 2021, Willsmore et al, 2019. Development of alopecia areata (AA) after initiating dupilumab has also been reported (Kanda et al, 2019, Maloney et al, 2019, Ständer et al, 2020.…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Kamata

Tada

2021

JID Innovations

View full text Add to dashboard Cite

show abstract

“…The initial severity of the pain appears to be predictive of the overall severity, as patients who originally had mild symptoms were generally able to continue dupilumab without significant worsening. 3 , 9 Meanwhile, those with moderate or severe pain at onset were more likely to discontinue dupilumab. 3 Many cases showed that the joint symptoms in mild and some moderate cases could be managed well with nonsteroidal anti-inflammatory drugs, and the clinical benefit from dupilumab outweighed any lingering inflammatory arthritis, according to the patients.…”

Section: Discussionmentioning

confidence: 99%

“… 3 Many cases showed that the joint symptoms in mild and some moderate cases could be managed well with nonsteroidal anti-inflammatory drugs, and the clinical benefit from dupilumab outweighed any lingering inflammatory arthritis, according to the patients. 2 , 3 , 9 , 10 , 11 Several recommendations can be made at this point, despite the clear need for additional information about this emerging adverse event. We have summarized our recommendations in Table II .…”

Section: Discussionmentioning

confidence: 99%

Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management

2022

View full text Add to dashboard Cite

“…In most cases, the symptoms were mild and did not require discontinuation of DUP. However, in cases of moderate-to-severe arthritis, administration of nonsteroidal anti-inflammatory drugs or discontinuation of DUP was necessary (59)(60)(61)(62)(63)(64)(65). Bostan et al reported a case of reactivation of inflammatory monoarthritis during DUP therapy (66).…”

Section: Arthritismentioning

confidence: 99%

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Guglielmo,

Deotto,

Naldi

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy, focusing primarily on the use of biologics and small molecules. In response to advancing knowledge of AD's causes and treatments, there's a global need for updated guidelines to provide physicians with a more comprehensive clinical perspective, facilitating personalized treatment strategies. Dupilumab, a groundbreaking biologic, gained approval as a significant milestone. Clinical trials demonstrated its ability to significantly reduce AD severity scores, with an impressive 37% of patients achieving clear or nearly clear skin within just 16 weeks of treatment. Real-world studies further support its efficacy across various age groups, including the elderly, with a safety profile akin to that of younger adults. Tralokinumab, a more recent approval, shows promise in clinical trials, particularly among younger populations. However, its real-world application, especially in older individuals, lacks comprehensive data. JAK inhibitors like Upadacitinib, baricitinib, and abrocitinib hold substantial potential for AD treatment. Nevertheless, data remains limited for patients over 75, with older adults perceived to carry a higher risk profile. Integrated safety analyses revealed individuals aged 60 and above experiencing major adverse cardiovascular events and malignancies, underscoring the need for cautious consideration. While these therapies offer promise, especially among younger patients, further research is essential to determine their safety and efficacy in various populations, including pediatric, geriatric, and those with comorbidities. This review highlights the evolving landscape of AD treatment, with biologics and small molecules emerging as potent tools to enhance the quality of life for AD-affected individuals.

show abstract

Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib

Cited by 9 publications

References 4 publications

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis

Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Contact Info

Product

Resources

About